John G Ullman & Associates Inc. Buys 200 Shares of Illumina, Inc. (NASDAQ:ILMN)

John G Ullman & Associates Inc. increased its position in Illumina, Inc. (NASDAQ:ILMN) by 1.2% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 17,150 shares of the life sciences company’s stock after buying an additional 200 shares during the period. John G Ullman & Associates Inc.’s holdings in Illumina were worth $2,237,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the business. Primecap Management Co. CA grew its stake in shares of Illumina by 3.6% during the third quarter. Primecap Management Co. CA now owns 2,516,359 shares of the life sciences company’s stock valued at $328,158,000 after buying an additional 87,599 shares during the last quarter. Intech Investment Management LLC increased its holdings in Illumina by 161.6% during the 3rd quarter. Intech Investment Management LLC now owns 7,845 shares of the life sciences company’s stock worth $1,023,000 after purchasing an additional 4,846 shares during the period. Moors & Cabot Inc. lifted its holdings in shares of Illumina by 1.7% in the 3rd quarter. Moors & Cabot Inc. now owns 5,818 shares of the life sciences company’s stock worth $759,000 after buying an additional 95 shares during the period. Connor Clark & Lunn Investment Management Ltd. grew its position in shares of Illumina by 1,073.8% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 125,126 shares of the life sciences company’s stock worth $16,318,000 after buying an additional 114,466 shares in the last quarter. Finally, NS Partners Ltd raised its holdings in shares of Illumina by 2.5% in the 3rd quarter. NS Partners Ltd now owns 37,103 shares of the life sciences company’s stock valued at $4,839,000 after purchasing an additional 900 shares in the last quarter. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Illumina Stock Performance

Shares of NASDAQ ILMN opened at $131.68 on Thursday. The stock’s 50 day simple moving average is $140.18 and its 200 day simple moving average is $124.52. Illumina, Inc. has a 12-month low of $93.51 and a 12-month high of $156.66. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.26. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The business had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.08 billion. During the same quarter in the prior year, the firm posted $0.33 earnings per share. The company’s revenue was down 3.5% on a year-over-year basis. Research analysts expect that Illumina, Inc. will post 4.11 earnings per share for the current year.

Analysts Set New Price Targets

ILMN has been the topic of a number of recent analyst reports. Daiwa America raised Illumina to a “strong-buy” rating in a research report on Friday, August 16th. UBS Group lifted their target price on shares of Illumina from $133.00 to $145.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Robert W. Baird raised their price objective on Illumina from $124.00 to $139.00 and gave the company a “neutral” rating in a report on Wednesday, November 6th. Canaccord Genuity Group raised their price objective on shares of Illumina from $130.00 to $145.00 and gave the stock a “hold” rating in a research report on Tuesday, November 5th. Finally, Stephens lifted their price target on shares of Illumina from $170.00 to $184.00 and gave the company an “overweight” rating in a research report on Tuesday, November 12th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, fourteen have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, Illumina currently has a consensus rating of “Moderate Buy” and an average price target of $164.00.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.